Clinical Trial6 Nov 2026, 07:02 pm
Zydus Lifesciences: Saroglitazar Shows Promise in MASH Trial
AI Summary
Zydus Lifesciences announced positive Phase 2b clinical trial results for its investigational drug, saroglitazar, in adults with metabolic dysfunction-associated steatohepatitis (MASH) and stage F2-F3 fibrosis. The trial, presented at AASLD 2026, showed that 39.1% of patients receiving 4 mg of saroglitazar magnesium achieved resolution of steatohepatitis without worsening of fibrosis, compared to 13.7% on placebo. The drug was generally well-tolerated with no significant weight gain or liver injury signals. These findings support further evaluation of saroglitazar in larger studies for MASH treatment.
Key Highlights
- Phase 2b trial shows saroglitazar achieved MASH resolution without fibrosis worsening.
- 39.1% of patients on 4mg saroglitazar met primary endpoint vs 13.7% placebo.
- Investigational drug was well-tolerated with no significant safety concerns.
- Results support further clinical development for MASH treatment.
Price Impact
More from ZYDUSLIFE